Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ariad, Icon Medical Corp. deal

Icon received non-exclusive rights to use ARIA's deforolimus ( AP23573)

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE